Page 8 - Nifty Pharma

Nifty Pharma index surges 4%; Sun Pharma, Cipla hit 52-week highs

At 12:57 pm, Nifty Pharma index, the top gainer among sectoral indices, was up 4.2 per cent, as compared to 1.3 per cent gain in the benchmark Nifty50 index

Nifty Pharma index hits new record high; Laurus Labs, Glenmark Pharma up 3%

Cipla, Cadila Healthcare, Lupin, Sun Pharma and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the NSE

Time to invest in cyclicals as economic recovery gathers steam: Analysts

Despite the large economic impact of the Covid-19 pandemic, the markets have recovered sharply even though the performance among individual stocks has been quite polarised

Dr Reddy's: Progress in Covid vaccine trials to boost firm's growth outlook

Good momentum in US and domestic sales, along with Covid-19 treatment portfolio is already driving analysts to upgrade earnings estimates

Vaccine majors see sharp rally with some players rising more than 4,000%

The Indian pharmaceutical sector has also been going through a surge

Nifty Pharma index rallies nearly 3%; Lupin surges 10%, Cipla, Cadila up 3%

All the 10 constituents of the Nifty Pharma index were trading in the green.

Market Wrap, May 13: Here's All That Happened In The Markets Today

Sectorally, banking stocks rallied the most. The Nifty PSU Bank index jumped over 6 per cent to 1,238.05 while Nifty Bank climbed over 4 per cent to 19,635

Street signs: Banking stocks under pressure, FPI tally gets skewed and more

The performance of banking stocks is likely to weigh on the markets

Pharma stocks rally; Nifty Pharma index surges 10%, Ipca Labs hits new high

Torrent Pharmaceuticals also rose 15 per cent to a fresh 52-week high of Rs 2,380

Select pharma shares in focus, Nifty Pharma rebounds 16% from day's low

Aurobindo Pharma moved higher by 20 per cent to Rs 449, and witnessed 32 per cent rally in the intra-day deal.

Market Wrap, March 3: Sensex snaps 7-day losing streak, gains 480 pts

Sectorally, metal and pharma stocks gained the most. Nifty Metal index climbed 5.6 per cent to 2,321 levels while Nifty Pharma index ended at 7,921, up over 5 per cent

Pharma shares gain; Dr Reddy's, Alembic, Divis, Laurus Labs hit 52-wk highs

Wockhardt, Strides Pharma Science, Alembic Pharmaceuticals, Pfizer and IOL Chemicals & Pharmaceuticals were up in the range of 5 per cent to 9 per cent in intra-day trade today.

Glenmark and Lupin: Are pharma stocks a good contrarian bet?

Glenmark Pharma is continuously going down from Rs 600 levels and is not showing any sign of recovery.

Nifty Pharma index hits 5-year low; Glenmark at 7-year low post Q1 results

Glenmark Pharmaceuticals plunged 9 per cent, while Dr Reddy's slipped 8 per cent in intra-day trade

Tech view: Nifty Pharma is headed for a strong rally; watch for 9350 levels

In the last five sessions, the index has been hovering at 200-days moving average (DMA) located around 9230, as per daily chart. A major trigger for a bigger run stays at 9350 levels

Sector Watch: Nifty Pharma index slips up to 3% dragged by Sun Pharma

Nifty Pharma index emerged as the top sectoral loser on NSE in the morning deals on Monday, weighed down by the shares of Sun Pharmaceutical Industries, which slumped as much as 10 per cent.

Nifty Pharma index rises 2% as Sun Pharma, Lupin receive USFDA approval

Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-angle Glaucoma or Ocular Hypertension.

Nifty Pharma index hits 52-week high; Cipla, Sun Pharma touch 52-week highs

Nifty Pharma index hit a 52-week high of 10,142, rising 2%, in early morning deal, surpassing its previous high of 10,063 recorded on November 3, 2017 in intra-day trade on the NSE.

Nifty Pharma index set to post biggest weekly rally in 15 years

At 11:23 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week.

Pharma stocks on a booster dose; Nifty Pharma up 12% in six days

Analysts attribute the run-up in pharma stocks to positive corporate announcements on the US drug regulatory front